Aayushi Pratap, Forbes Staff

Author's posts

Booster Shot Generates Antibodies Against Omicron And Delta Variants, Says Indian Vaccine Maker

Bharat Biotech has already distributed around 180 doses of its Covaxin in India and has exported or donated 3 million doses across the world.

Indian Pharmaceutical Manufacturers Are Ready To Bring Covid Antivirals To The World

Manufacturers in India are gearing up to produce generic versions of Pfizer and Merck’s antivirals and can make millions of pills a month. They just need regulators to give them the okay.

This Company Has Applied For Authorization In India For Its Nasal Spray That Prevents Covid

Ireland-based pHOXBIO’s medicine was shown to provide protection against Covid in clinical trials.

Tesla’s India Fans Are Eager To Buy Elon Musk’s Cars, But Politics Is Getting In The Way

The company is at a standoff with the Modi government, which wants Musk to commit to building electric vehicles locally before waiving steep tariffs.

Inside Freshworks’ Rise From India Enterprise Tech Startup To $10 Billion IPO

CEO Girish Mathrubootham wanted to show that world-class products can come from India. Going public in the U.S. wasn’t part of the plan.

Vicarious Surgical Starts Trading As It Prepares To Launch Its Surgical Robots — And Take On Intuitive

Under 30 alums Adam Sachs and Sammy Khalifa founded Vicarious Surgical in 2014. Today, their company starts trading on the NYSE under the ticker RBOT.

This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases

iECURE aims to use gene editing to treat patients suffering from rare genetic disorders.

Indian Government Authorizes Needle-Free Covid Vaccine

The DNA vaccine, developed by Indian company Zydus Cadila, is the second Indian-developed Covid vaccine to get a regulatory thumbs up.

Experts Say The Biden Administration’s Plan For Booster Shots Could Hinder The Global Fight Against The Pandemic

Less than a third of the population is vaccinated against Covid, and most of those people live in wealthier nations.

Pfizer Expects $33.5 Billion In Vaccine Revenue In 2021

In its earnings report Wednesday, the company also emphasized data showing the need for Covid booster shots.